Immunocore (NASDAQ:IMCR) Posts Earnings Results, Misses Expectations By $0.16 EPS

Immunocore (NASDAQ:IMCR) released its earnings results on Wednesday. The company reported ($0.47) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.16), Zacks reports. Immunocore had a negative return on equity of 12.84% and a negative net margin of 15.87%.

Immunocore Trading Up 6.1 %

Immunocore stock traded up $1.78 during trading hours on Wednesday, reaching $30.99. The company had a trading volume of 96,158 shares, compared to its average volume of 217,701. The company has a debt-to-equity ratio of 1.03, a current ratio of 3.78 and a quick ratio of 3.76. Immunocore has a 12-month low of $27.69 and a 12-month high of $72.56. The company has a 50-day moving average price of $29.98 and a 200 day moving average price of $31.97. The firm has a market cap of $1.55 billion, a price-to-earnings ratio of -32.62 and a beta of 0.77.

Analyst Upgrades and Downgrades

A number of research firms recently commented on IMCR. HC Wainwright reaffirmed a “buy” rating and set a $100.00 price target on shares of Immunocore in a research report on Monday, January 27th. Mizuho cut shares of Immunocore from an “outperform” rating to a “neutral” rating and decreased their target price for the stock from $72.00 to $38.00 in a research note on Monday, November 11th. Morgan Stanley reiterated an “equal weight” rating and issued a $35.00 target price (down from $74.00) on shares of Immunocore in a report on Friday, December 13th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $71.00 target price on shares of Immunocore in a research report on Friday, January 10th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $65.64.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.